Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Lab/Research institutions
We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.
We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.
We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.
We make our efforts to offer customer innovative, customized, high-quality service.
Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.
UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3. IC50 value: 0.8/0.74 nM(MER/FLT3) Target: Mer/Flt3 inhibitor UNC2025 was capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow. Kinome pro ling versus more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an additional important target in acute myelogenous leukemia (AML), with pharmacologically useful selectivity versus other kinases examined.